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ABSTRACT
Germline mutations in BRCA1 and BRCA2 (BRCA1/2) are associated with increased 
risk of breast and ovarian cancer. The penetrance of breast and ovarian cancer in 
BRCA1/2 mutation carriers has been well characterized in Caucasian but not in Asian. 
Two studies have investigated the breast cancer risk in Asian women with BRCA1/2 
mutations, and no published estimates are available for ovarian cancer. Therefore, we 
estimated the age-specific cumulative risk of BRCA1/2-associated breast and ovarian 
cancer in Chinese women. From Jan 2007 to Nov 2015, the Hong Kong Hereditary 
Breast Cancer Family Registry identified 1635 families with hereditary breast-ovarian 
cancer. Among probands in these families, 66 had BRCA1 mutations, 84 had BRCA2 
mutations, and 1,485 tested negative for BRCA1/2 mutations. Using the female first-
degree relatives of these probands, we estimated the risk of breast and ovarian cancer 
using a modified marginal likelihood approach. Estimates of breast cancer penetrance 
by age 70 were 53.7% (95% CI 34.5-71.6%) for BRCA1 mutation carriers and 48.3% 
(95% CI 31.8-68.5%) for BRCA2. The estimated risk of ovarian cancer by age 70 was 
21.5% and 7.3% for Chinese women carrying BRCA1 or BRCA2 mutation respectively. A 
meta-analysis of available studies in Asian women revealed pooled estimates of breast 
cancer risk by age 70 of 44.8% (95% CI 33-57.2%) and 40.7% (95% CI 31.3-50.9%) 
for BRCA1 and BRCA2 mutation carriers respectively. These data suggest that BRCA1/2-
associated breast cancer risk for Chinese women is similar to that for Caucasian women, 
although BRCA1/2-associated ovarian cancer risks are lower for Chinese women.
INTRODUCTION
BRCA1 and BRCA2 (BRCA1/2) are human tumor 
suppressor genes which play a role in DNA damage repair 
and transcriptional regulation [1]. Germline mutations in 
BRCA1/2 are associated with an increased risk and early 
age onset for hereditary breast and ovarian cancer [2]. 
Genetic counseling is now routinely offered to individuals 
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with high-risk of carrying a BRCA1 or BRCA2 mutation. 
Correspondingly, personalized prevention strategies will 
be offered according to their risk level, which is often 
assessed through a risk prediction model. Thus, risk 
assessment in BRCA1/2 mutation carriers is of great 
importance in clinical service and cancer management.
The risk estimates of breast and ovarian cancer in 
BRCA1/2 mutation carriers have been well characterized 
for Caucasian women and individuals of Ashkenazi-
Jewish background [2–4]. According to the most recent 
meta-analysis, the cumulative breast cancer risk by age 
70 years was estimated to be 55% (95% CI: 50-59%) and 
47% (95% CI: 42-51%) for Caucasian women carrying a 
BRCA1 or BRCA2 mutation respectively. The estimates of 
ovarian cancer penetrance by age 70 were 39% (95% CI: 
34-45%) for BRCA1 mutation carriers and 17% (95% CI: 
13- 21%) for BRCA2 mutation carriers. Since the mutation 
frequency and cancer incidence vary by ethnic groups 
[5, 6], these estimates cannot be extrapolated to a large 
outbred population such as East Asia.
The contribution of BRCA1 and BRCA2 mutations 
to breast and ovarian cancer incidence has not been well 
explored in Asian population, where both cancer incidence 
and mutation prevalence are lower compared to western 
countries [7, 8]. So far only two studies have investigated 
breast cancer risk in Asian women with BRCA1/2 
mutations. Yao et al. identified 70 BRCA1 and 55 BRCA2 
mutation-carrying families from 1,816 unselected Chinese 
women with breast cancer, and estimated the breast cancer 
risk by age 70 as 37.9% (95% CI: 24.1-54.4%) for BRCA1 
and 36.5% (95% CI: 26.7-51.8%) for BRCA2 using a kin-
cohort design [9]. Park et al. reported their estimates for 
Korean women based on 151 BRCA1 and 225 BRCA2 
mutation-carrying families using a modified segregation 
analysis [10]. According to their study, Korean women 
with BRCA1 mutation had a cumulative risk of 49% (95% 
CI: 11-98%) for development of breast cancer by age 
70, and the risk was 35% (95% CI: 16-65%) for BRCA2. 
However, there is no published ovarian cancer estimates 
associated with these mutations in Asian women.
The aim of our study is to estimate breast and 
ovarian cancer risk in Chinese female BRCA1/2 mutation 
carriers using a more efficient method based on a 
relatively large study population. We will also conduct 
a meta-analysis to integrate available estimates of breast 
cancer risk in Asian women carrying a BRCA1 or BRCA2 
germline mutation into a consensus estimate of penetrance.
RESULTS
A total of 66 BRCA1, 84 BRCA2, and 1,485 
mutation-negative families were included in our study. The 
mutation frequencies in this sample of high-risk families 
for BRCA1 and BRCA2 were estimated as 2.1% and 2.7% 
respectively. Data for the 5,949 first-degree relatives was 
utilized to obtain estimates of breast cancer penetrance in 
mutation carriers (230 from BRCA1 carrier relatives, 309 
from BRCA2 carrier relatives and 5,410 from non-carrier 
relatives). Although most of the first-degree relatives were 
un-genotyped (67.4%, 73.1%, and 99.6% for BRCA1, 
BRCA2 and non-carrier relatives respectively), 16.1% and 
14.6% of first-degree relatives were confirmed mutation 
carriers for BRCA1 and BRCA2 relatives respectively, and 
16.5% and 12.3% were confirmed non-carriers.
Table 1: Number and age at diagnosis of breast and ovarian cancer cases in BRCA1, BRCA2, and non-carrier 













No. (%) Mean (SE) Median (IQR) No. (%) Mean (SE) Median (IQR)
Probands
 BRCA1 58 (87.9) 41.8 (1.2) 40 (35-48) 17 (25.8) 47.1 (2.0) 45 (41-52)
 BRCA2 83 (98.8) 43.4 (0.9) 42 (37-49) 4 (4.8) 46.5 (0.9) 46 (45.5-47.5)





 BRCA1 49 (21.3) 45.1 (1.8) 42 (36-53) 20 (8.7) 50.4 (1.6) 50 (45-55)
 BRCA2 63 (20.4) 45.8 (1.5) 45 (38-50) 5 (1.6) 66.0 (4.8) 62 (61-69)
 Non-carrier 456 (8.4) 51.1 (0.5) 50 (44-58) 42 (0.8) 49.0 (2.4) 49 (35-60)
IQR: Interquartile range.
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Risk of breast cancer in first-degree relatives
A total of 568 breast cancer cases occurred in 
first-degree relatives, with an incidence of 21.3%, 20.4, 
and 8.4% for BRCA1, BRCA2 and non-carrier families, 
respectively (Table 1). The risk of breast cancer in the 
first-degree relatives of BRCA1 and BRCA2 probands 
was significantly higher than in first-degree relatives of 
non-carrier families (hazard ratio, HR=3.31, 95% CI 2.46-
4.44, p<0.001; HR=3.31, 95% CI 2.46-4.44, p<0.001 for 
BRCA1 and BRCA2 respectively). For probands, the mean 
age at diagnosis of breast cancer in BRCA1 carriers was 
significantly earlier than non-carrier (41.8 vs 44.8 years, 
p=0.02). There was no significant difference in age at 
diagnosis between BRCA1 and BRCA2 carrier families 
(41.8 vs 43.4 years, p=0.28) nor BRCA2 carrier families 
and non-carrier families (43.4 vs 44.8 years, p=0.22). 
The results were similar for the first-degree relatives. The 
mean age at diagnosis in first-degree relatives of BRCA1 
carriers or BRCA2 carriers was significantly earlier than 
that of non-carrier families (45.1 vs 51.1 years, p=0.0005; 
45.8 vs 51.1 years, p=0.0005). There was no significant 
difference between BRCA1 and BRCA2 families (45.1 vs 
45.8 years, p=0.76).
Age-specific penetrance of breast cancer in 
mutation carriers
The estimated penetrance of breast cancer in BRCA1 
mutation carriers by age 70 years was 53.7% (95% CI: 
34.5-71.6%) (Table 2 & Figure 1), which is higher than 
that for Korean women reported by Park et al., 49% (95% 
CI: 11-98%) [10], and for Chinese women reported by Yao 
et al., 37.9% (95% CI: 24.1-54.4%) [9]. Estimates by age 
40, 50, 60, 70 years from all three studies were shown in 
Table 3. The meta-analytic estimate of penetrance by age 
70 years based on these three studies was 44.8% (95% 
CI: 33-57.2%) (Test for heterogeneity: p=0.49). The meta-
analytic estimates were 5.2% (95% CI: 1.3-18.2%), 13.6% 
(95% CI: 8.9-20.3%), and 30.9% (95% CI: 21.5-42.2%) 
for age intervals 20 to 40, 20 to 50, and 20 to 60 years, 
respectively.
Table 2: Age-specific penetrance of breast cancer (×100) by BRCA1 and BRCA2 mutation status, estimated using 
data from the first-degree relatives by the modified kin-cohort method
BRCA1 carrier BRCA2 carrier Non-carrier
Age Interval Penetrance (95% CI) Penetrance (%) (95% CI) Penetrance (%) (95% CI)
20-40 years 10.0 (4.7-15.7) 6.7 (3.2-11.0) 1.1 (0.8-1.5)
20-50 years 16.3 (8.6-25.0) 21.1 (12.3-31.1) 6.3 (5.4-7.2)
20-60 years 30.5 (18.0-46.6) 31.4 (21.6-42.6) 11.8 (10.5-13.0)
20-70 years 53.7 (34.5-71.6) 48.3 (31.8-68.5) 16.1 (14.3-17.8)
Figure 1: Breast cancer penetrance estimates by the modified kin-cohort method using data from first-degree relatives 
of probands who carry BRCA1 or BRCA2 mutations from Hong Kong Hereditary and High Risk Breast Cancer 
Programme.
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Similarly, for BRCA2 mutation carriers, the 
estimated penetrance of breast cancer by age 70 years 
was 48.3% (95% CI: 31.8-68.5%) (Table 2 & Figure 1), 
which is similar to Korean women, 35% (95% CI: 16-
65%)[10] and Chinese women in Beijing, 36.5% (95% 
CI: 26.7-51.8%) [9] (Table 3). The meta-analytic estimate 
of penetrance by age 70 years based on these three studies 
was 40.7% (95% CI: 31.3-50.9%) (Test for heterogeneity: 
p=0.16). The meta-analytic estimates were 4.5% (95% 
CI: 1.8-10.7%), 15.8% (95% CI: 10.1-24.1%), and 29.6% 
(95% CI: 23.1-36.9%) for age intervals 20 to 40, 20 to 50, 
and 20 to 60 years, respectively.
Age-specific penetrance for ovarian cancer
The estimated penetrance of ovarian cancer by age 
70 years was 21.5% (95% CI: 10.4-37.0%) for BRCA1 
mutation carriers and 7.3% for BRCA2 mutation carriers. 
The penetrance estimate by age 60 years was 13.7% 
(95% CI 6.6-24.3%) for BRCA1 mutation carriers and 
1.3% for BRCA2 mutation carriers (Table 4 & Figure 2). 
The number of ovarian cancer cases among BRCA2 
carriers was too small to permit reasonable estimation of 
confidence intervals.
DISCUSSION
BRCA1/2 mutations are known to increase the 
lifetime risk of breast cancer by 50-87% and ovarian 
cancer by 10-40%, based on data derived primarily from 
Caucasians [2]. BRCA1/2 mutation carriers have been 
managed based on the existing guidelines such as NCCN 
guidelines. These guidelines include more intensive 
screening, risk-reducing surgeries such as mastectomy 
and salpingo-oopherectomy, and even the use of specific 
types of chemotherapy such as platinum agents or 
targeted therapy such as poly (ADP-ribose) polymerase 
(PARP) inhibitors [15, 16]. Our current data revealed 
that the cumulative risks of ovarian cancer in Chinese is 
lower than that of the Caucasians, preventive surgery (e.g. 
salpingo-oopherectomy) maybe “overtreated” the patients 
or those healthy individuals who harbor the mutations. 
Hence, screening of germline BRCA1/2 mutations is 
crucial for appropriate clinical management of cancer 
risk, yet more studies on the prevalence and cumulative 
breast cancer risk for these genes in Asian women are 
warranted.
We reported the first large-scale estimate of 
BRCA1/2 prevalence in Southern Chinese families, 
ascertained through patients with triple negative breast 
cancer and those that had a family history of breast 
and/or ovarian cancers. These women have an elevated 
chance of carrying BRCA1/2 mutations [11]. There was 
also a difference in the observed spectrum of mutations 
where over 40% of the BRCA mutations were novel and 
had never been reported. We previously also collected 
data from a BRCA consortium with 47 Asian countries 
and Asian population residing in North America on all 
the BRCA mutations in breast cancer patients [17]. The 
prevalence of BRCA mutations varies in different Asian 
cohorts, with 21.7% (BRCA1 9.3%; BRCA2 12.4%) in 
patients with family history of breast or ovarian cancer 
in Korea [18] and 17% (BRCA1 11%; BRCA2 6%) in 
Malaysian patients with early onset of breast cancer [19]. 
In the present study, our Southern Chinese population had 
a higher BRCA1 mutation than BRCA2 mutation than in 
Table 3: Meta-analytic estimates of breast cancer penetrance (× 100) in Asian women who carry BRCA1 or BRCA2 
mutations
Study Korea Beijing Hong Kong Meta-analytic Estimates








 20-40 years 10 (2-45) 2.2 (0-4.4) 10.0 (4.7-15.7) 5.2 (1.3-18.2)
 20-50 years 27 (5-84) 9.9 (3.3-17.2) 16.3 (8.6-25.0) 13.6 (8.9-20.3)
 20-60 years 41 (9-95) 29.3 (17.6-47.1) 30.5 (18.0-46.6) 30.9 (21.5-42.2)
 20-70 years 49 (11-98) 37.9 (24.1-54.4) 53.7 (34.5-71.6) 44.8 (33.0-57.2)
BRCA2
 20-40 years 6 (3-15) 1.2 (0-3.1) 6.7 (3.2-11.0) 4.5 (1.8-10.7)
 20-50 years 18 (8-39) 10.7 (9.6-16.9) 21.1 (12.3-31.1) 15.8 (10.1-24.1)
 20-60 years 28 (13-56) 27.2 (19.0-38.5) 31.4 (21.6-42.6) 29.6 (23.1-36.9)
 20-70 years 35 (16-65) 36.5 (26.7-51.8) 48.3 (31.8-68.5) 40.7 (31.3-50.9)
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Mainland China (BRCA1 10.6%; BRCA2 5.2%), despite 
there were disparities in the selection criteria in each study 
[20]. In Hong Kong, the prevalence of BRCA1/2 mutations 
was 9.4%, and a slightly higher BRCA2 mutation rate was 
observed [11]. Considering patients with triple-negative 
breast cancer, BRCA1 mutation dominancy was seen in 
both Asian and Caucasian populations [17].
It is important to know the estimated risk for women 
who carry BRCA mutations, so that high risk patients can 
be identified for genetic screening and better surveillance 
options and treatment can be implemented in the genetic 
counseling. Risk prediction models such as BOADICEA, 
BRCAPRO and Myriad models are designed for the 
estimation of risk among women carrying a BRCA 
mutation in hereditary breast cancers [21, 22]. These 
prediction tools have been developed based on different 
ethnic groups and with slight difference in predictive 
factors. Therefore, their performance needs to be validated 
for the selection of high risk patients [23, 24]. In view 
of this, we adopted the kin-cohort approach which treated 
the first-degree relatives of the probands as an ascertained 
cohort to the present study and modified the R kin. cohort 
package to improve the efficiency [13]. Meta-analytic 
penetrance estimates of BRCA1 and BRCA2 mutations 
in Asian carriers (results from three cohort studies) were 
44.8% and 40.7% respectively. In general, Hong Kong has 
the highest estimated risk of breast cancer by age 70 years 
for both BRCA1 and BRCA2 carriers, but still much lower 
than that in Caucasians (40-87% for BRCA1 and 27-84% 
for BRCA2) [25, 26]. The cumulative estimates of ovarian 
cancer in Caucasians ranged from 16-68% and 11-27% 
for BRCA1 and BRCA2 carriers respectively, which are 
in line with our findings that BRCA2 carriers tend to have 
a lower risk of ovarian cancer [25, 26]. The variability of 
these estimates can be influenced by other non-genetic and 
environmental factors (e.g. breast feeding, pregnancy and 
radiation exposure) [27].
To the best of our knowledge, this is the first study 
to report the penetrance of BRCA mutation carriers in the 
Hong Kong Chinese population with breast and ovarian 
cancers, which differs from that in Caucasian populations. 
In this study, the ovarian cancer estimates was found to 
be different from that of the Caucasians. The cumulative 
estimates of breast cancer were similar, but the ethnicity-
Table 4: Age-specific penetrance of ovarian cancer (× 100) by BRCA1 and BRCA2 mutation status, estimated using 
data from the first-degree relatives by the modified kin-cohort method
BRCA1 carrier BRCA2 carrier Non-carrier
Age Interval Penetrance (%) (95% CI) Penetrance (%) (95% CI) Penetrance (%) (95% CI)
30-50 years 5.0 (1.8-13.3) - 0.4 (0.2-0.6)
30-60 years 13.7 (6.6-24.3) 1.31 0.7 (0.4-1.0)
30-70 years 21.5 (10.4-37.1) 7.31 1.4 (0.9-1.9)
1Number of events too small to allow for reasonable estimates of confidence intervals.
Figure 2: Ovarian cancer penetrance estimates by the modified kin-cohort method using data from first-degree 
relatives of probands who carry BRCA1 or BRCA2 mutations from Hong Kong Hereditary and High Risk Breast 
Cancer Programme.
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specific estimates are more relevant in terms of clinical 
management and surveillance. Hence, clinicians and 
genetic counselors need to be cautious when quoting 
cancer risk estimates from the Western data in explaining 
genetic test results to patients. Better understanding of the 
difference in penetrance and cancer risks would mean that 
present guidelines based on Western data may need to be 
modified to better suit ethnicities. Nevertheless, large-
scale multicenter studies in different regions of China will 
enhance the estimation of the overall cancer risk in BRCA 
carriers with Chinese ethnicity. Genetic counseling and 
testing services are not a common practice in Mainland 
China and other Asian countries, except for Korea, mainly 
because of the limited access to qualified laboratory and 
healthcare professionals, and also resources for laboratory 
and clinical services are scanty [28]. Although genetic 
testing is very much standard care in the West, there is 
still limited resource to support testing and allow more 
popularized genetic testing in Asia. As more prevalence 
and spectrum data of Asian ethnicities emerges which is 
found to diverge from the West, estimated penetrance from 
larger cohort studies is needed to better guide patient care 
in these high-risk cohorts.
MATERIALS AND METHODS
Ethics statement
The study was performed in accordance with the 
Declaration of Helsinki. Written informed consent was 
obtained from all participants recruited in this study. This 
study was approved by the Institutional Review Board of 
the University of Hong Kong/Hospital Authority West 
Cluster and other contributing hospitals in Hong Kong 
(UW-16-274 T1299).
Study participants
In this study, a total of 1,635 Chinese families 
were recruited at the Hong Kong Hereditary Breast 
Cancer Family Registry from Jan 2007 to Nov 2015. The 
patient selection criteria were described previously [11]. 
A standard epidemiological questionnaire, including a 
detailed family history, was administered to patients and 
medical information, including pathology reports, was 
retrieved from the patient’s medical records. Information 
from the epidemiological questionnaire included age at 
breast/ovarian cancer diagnosis, other cancers diagnosed 
in the patient, and a family history of breast, ovarian, 
and other cancers in first, second, and third degree 
relatives. Also, the date for preventive bilateral risk-
reducing salpingo-oophorectomy, bilateral risk-reducing 
mastectomy, last follow-up or death were collected. This 
cohort of families who were previously characterized by 
Sanger sequencing and 1,100 probands were subjected to 
NGS screening. Concurrent with sequencing, all patients 
were tested for large genomic rearrangement of BRCA1 
and BRCA2 by multiplex ligation-dependent probe 
amplification (MLPA). Characteristics of patient cohorts 
were shown in Table 5.
All male relatives were excluded from the study 
due to gender difference in breast cancer penetrance. 
Only first degree relatives were included in the analysis 
due to lack of statistical methodology for incorporating 
distant relatives. Previous study showed that patients with 
triple negative breast cancer and those that had a family 
history of breast and/or ovarian cancers have increased 
risk of carrying BRCA1/2 mutations [11]. 66 female 
BRCA1 carrier probands were identified, and age-at-onset 
data for 1,747 relatives were collected. 230 first-degree 
relatives were included in the analysis, with 66 mothers, 


















First Degree Relatives 230 (77.7) 3 (2-4) 309 (78.6) 3 (2-4) 5410 (78.4) 3 (2-5)
Mother 66 (28.7) 1 (1-1) 84 (27.2) 1 (1-1) 1485 (27.4) 1 (1-1)
Daughter 37 (16.1) 0 (0-1) 48 (15.5) 0 (0-1) 967 (17.9) 0 (0-1)
Sister 127 (55.2) 1 (1-3) 177 (57.3) 2 (1-3) 2958 (54.7) 2 (1-3)
Carriers 37 (16.1) 1 (1-2) 45 (14.6) 1 (1-2) 1 (<0.1) 0 (0-0)
Non-carriers 38 (16.5) 0 (0-1) 38 (12.3) 0 (0-1) 19 (0.4) 1 (1-1)
Un-genotyped 155 (67.4) 2 (1-3) 226 (73.1) 2 (1-3) 5390 (99.6) 3 (2-5)
IQR: Interquartile range.
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37 daughters and 127 sisters (Supplementary Figure 1). 
Among the 230 first-degree relatives, 37 were confirmed 
BRCA1 mutation carriers, 38 non-carriers, and 155 were 
not tested.
Moreover, 84 female BRCA2 carrier probands 
were recruited, with information on 2,330 relatives 
(1,145 male vs. 1,185 female) available. 309 female 
first-degree relatives, including 84 mothers, 48 daughters 
and 177 sisters, were included in the current analysis 
(Supplementary Figure 2). Of those, 45 were confirmed 
BRCA2 mutation carriers, 38 non-carriers, and 226 were 
not tested. In addition, 1,485 non-carrier female probands 
provided information for 40,015 relatives. Of 5,410 first-
degree relatives (1,485 mothers, 967 daughters, 2,958 
sisters), only 1 was BRCA2 positive, 19 were BRCA1/2 
negative, and the rest were not tested (Supplementary 
Figure 3).
535 out of 7584 first degree relatives missed the 
time to event data (21, 22, 492 for BRCA1, BRCA2, 
negative proband respectively), and were excluded from 
the penetrance analysis. We then analyzed data from the 
remaining 5949 first degree relatives in the current study.
Statistical analysis
We analyzed the first-degree relatives of probands 
who were tested for BRCA1/2 mutations as a cohort, 
but corrected the bias due to the fact that the cohort was 
ascertained because probands had breast cancer. For breast 
cancer, the female first-degree relatives of the probands 
were followed from birth to the development of breast 
cancer (i.e., the primary event of interest), and were 
censored at the earliest date of ovarian cancer, preventive 
bilateral risk-reducing salpingo-oophorectomy, bilateral 
risk-reducing mastectomy, date of last follow-up, or death. 
For ovarian cancer, the follow-up was from birth to the 
development of ovarian cancer (i.e., the primary event of 
interest), or were censored at the earliest date of bilateral 
risk-reducing salpingo-oophorectomy, date of the last 
interview, or death. The age of diagnosis was compared 
across BRCA1, BRCA2, and non-carrier relatives using 
Student’s t test. To estimate age-specific penetrance of 
breast cancer in mutation carriers, we largely adopted a 
marginal likelihood approach for analyzing kin-cohort 
design where unavailable genotypes for the first-degree 
relatives were “imputed” from those of probands under 
Mendelian transmission [12]. We modified this approach 
to incorporate available genotypes for some of the first 
degree relatives to enhance statistical efficiency and 
implemented this modification using the R kin. cohort 
package (https://cran.r-project.org/web/packages/kin.
cohort/index.html). This method requires an estimate 
of the frequencies of BRCA1/2 mutations, which we 
calculated as half the carrier frequency in the index 
family members [13]. The 95% confidence intervals were 
obtained through the bootstrapping method using families 
as units.
We also conducted meta-analysis to integrate 
estimates from our current study with published estimates 
from Beijing and Korea [9, 10] and summarized in 
Supplementary Table 1. To date, the latter two were the 
only penetrance estimates available to date for breast 
cancer penetrance in BRCA1/2 mutation carriers in Asian 
women. Heterogeneity between studies was assessed using 
the χ2 test. The pooled estimate as well as 95% confidence 
intervals was obtained using the DerSimonian and Laird 
method [14]. All analyses were conducted using software 
R, and a test was considered statistically significant if a 
two-sided p-value was less than 0.05.
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